NLS PHARMACEUTICS LTD (NLSP) Fundamental Analysis & Valuation

NASDAQ:NLSP • CH1384053976

Current stock price

0.762 USD
+0.02 (+2.97%)
At close:
1.08 USD
+0.32 (+41.73%)
After Hours:

This NLSP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NLSP Profitability Analysis

1.1 Basic Checks

  • NLSP had negative earnings in the past year.
  • NLSP had a negative operating cash flow in the past year.
  • In the past 5 years NLSP always reported negative net income.
  • In the past 5 years NLSP always reported negative operating cash flow.
NLSP Yearly Net Income VS EBIT VS OCF VS FCFNLSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -181.68%, NLSP is doing worse than 87.50% of the companies in the same industry.
  • With a Return On Equity value of -288.47%, NLSP is not doing good in the industry: 72.40% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -181.68%
ROE -288.47%
ROIC N/A
ROA(3y)-339.54%
ROA(5y)-292.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NLSP Yearly ROA, ROE, ROICNLSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NLSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NLSP Yearly Profit, Operating, Gross MarginsNLSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NLSP Health Analysis

2.1 Basic Checks

  • NLSP has more shares outstanding than it did 1 year ago.
  • NLSP has less shares outstanding than it did 5 years ago.
  • NLSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NLSP Yearly Shares OutstandingNLSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NLSP Yearly Total Debt VS Total AssetsNLSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

  • NLSP has an Altman-Z score of -47.97. This is a bad value and indicates that NLSP is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -47.97, NLSP is doing worse than 90.63% of the companies in the same industry.
  • There is no outstanding debt for NLSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -47.97
ROIC/WACCN/A
WACCN/A
NLSP Yearly LT Debt VS Equity VS FCFNLSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

  • A Current Ratio of 2.69 indicates that NLSP has no problem at all paying its short term obligations.
  • NLSP has a Current ratio (2.69) which is in line with its industry peers.
  • A Quick Ratio of 2.69 indicates that NLSP has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.69, NLSP perfoms like the industry average, outperforming 55.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.69
NLSP Yearly Current Assets VS Current LiabilitesNLSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. NLSP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 77.00% over the past year.
EPS 1Y (TTM)77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.19%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NLSP Yearly EPS VS EstimatesNLSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. NLSP Valuation Analysis

4.1 Price/Earnings Ratio

  • NLSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NLSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NLSP Price Earnings VS Forward Price EarningsNLSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NLSP Per share dataNLSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NLSP Dividend Analysis

5.1 Amount

  • NLSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NLSP Fundamentals: All Metrics, Ratios and Statistics

NLS PHARMACEUTICS LTD

NASDAQ:NLSP (10/30/2025, 8:00:02 PM)

After market: 1.08 +0.32 (+41.73%)

0.762

+0.02 (+2.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-16
Earnings (Next)N/A
Inst Owners4.55%
Inst Owner Change0%
Ins Owners20.51%
Ins Owner ChangeN/A
Market Cap4.56M
Revenue(TTM)N/A
Net Income(TTM)-4.06M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.25
P/tB 3.25
EV/EBITDA N/A
EPS(TTM)-2.93
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS0.23
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -181.68%
ROE -288.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-339.54%
ROA(5y)-292.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.69
Altman-Z -47.97
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.39%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.24%
EPS Next Y97.19%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.93%
OCF growth 3YN/A
OCF growth 5YN/A

NLS PHARMACEUTICS LTD / NLSP Fundamental Analysis FAQ

What is the fundamental rating for NLSP stock?

ChartMill assigns a fundamental rating of 2 / 10 to NLSP.


What is the valuation status of NLS PHARMACEUTICS LTD (NLSP) stock?

ChartMill assigns a valuation rating of 0 / 10 to NLS PHARMACEUTICS LTD (NLSP). This can be considered as Overvalued.


What is the profitability of NLSP stock?

NLS PHARMACEUTICS LTD (NLSP) has a profitability rating of 0 / 10.


How financially healthy is NLS PHARMACEUTICS LTD?

The financial health rating of NLS PHARMACEUTICS LTD (NLSP) is 6 / 10.


What is the expected EPS growth for NLS PHARMACEUTICS LTD (NLSP) stock?

The Earnings per Share (EPS) of NLS PHARMACEUTICS LTD (NLSP) is expected to grow by 97.19% in the next year.